Details of Disease

Disease Name

Digestive system neoplasm

GI system tumour; tumour of the digestive system; GI tumor; gastrointestinal system tumour; tumor of gastrointestinal system; tumor of GI system; digestive tumor; tumour of the GI system; neoplasm of the gastrointestinal system; gastrointestinal neoplasm; gastrointestinal system neoplasm; gastrointestinal tumor; gastrointestinal system tumor; digestive tumour; tumor of digestive system; tumour of gastrointestinal system; GI system neoplasm; neoplasm of the digestive system; neoplasm of gastrointestinal system; neoplasm of digestive system; tumor of the gastrointestinal system; tumour of the gastrointestinal system; tumour of digestive system; tumour of GI system; GI neoplasm; GI system tumor; tumor of the GI system; digestive system tumor; neoplasm of the GI system; digestive system neoplasm (disease); digestive neoplasm; tumor of the digestive system; GI tumour; gastrointestinal tumour; digestive system tumour; neoplasm of GI system

Definition

A neoplasm (disease) that involves the digestive system.

Disease Hierarchy

DISTBY9Z: Tumour

DISPOJCT: Digestive system neoplasm

Disease Identifiers

MONDO ID

MONDO_0021223

MESH ID

D005770

UMLS CUI

C0017185

MedGen ID

4846

HPO ID

HP:0007378

SNOMED CT ID

126768004

General Information of Disease (ID: DISPOJCT)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACVR2A	TTX2DRI	Limited	Genetic Variation	[1]
CASP5	TTWR48J	Limited	Genetic Variation	[2]
EML4	TT92GY4	Limited	Biomarker	[3]
EPHA8	TTHZ2LW	Limited	Altered Expression	[4]
ERBB2	TTR5TV4	Limited	Biomarker	[3]
GRPR	TTC1MVT	Limited	Altered Expression	[5]
HBA2	TTQO71U	Limited	Biomarker	[6]
TPBG	TT70MLA	Limited	Biomarker	[7]
NPR3	TTWVLS6	Disputed	Altered Expression	[8]
GDF15	TT4MXVG	Strong	Therapeutic	[9]
HMGB2	TTA78JQ	Strong	Altered Expression	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DTT(s)

This Disease Is Related to 31 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADGRE2	OTUYJVYG	Limited	Biomarker	[11]
ADGRE5	OTTSB84Q	Limited	Biomarker	[11]
ATF1	OT251CI0	Limited	Biomarker	[12]
CELSR1	OT7PS8O1	Limited	Biomarker	[13]
E2F4	OTB3JFH4	Limited	Genetic Variation	[14]
EFNA2	OTEAUKRX	Limited	Altered Expression	[15]
GADD45G	OT8V1J4M	Limited	Biomarker	[16]
GNL3L	OTZYEFST	Limited	Altered Expression	[17]
IQCB1	OTYQ28V9	Limited	Biomarker	[18]
ISL1	OTVNVKAX	Limited	Altered Expression	[19]
MAP1LC3A	OTPMGIU4	Limited	Altered Expression	[20]
PIP	OTH719AH	Limited	Genetic Variation	[21]
PKP3	OTPL1HRB	Limited	Altered Expression	[22]
PRDM5	OTU1GB68	Limited	Genetic Variation	[23]
PTPRF	OTH5KF2D	Limited	Biomarker	[24]
RAD21	OTQS84ZF	Limited	Altered Expression	[25]
RASSF2	OT2JHDO4	Limited	Posttranslational Modification	[26]
TBX22	OTT1RM26	Limited	Biomarker	[27]
TLE6	OTB84O0U	Limited	Biomarker	[28]
PRR15	OTJHSY8G	Disputed	Biomarker	[29]
APC	OTKV0TIK	Strong	Biomarker	[30]
APOBEC1	OTY8QX2R	Strong	Altered Expression	[31]
CDH17	OT9EV2XK	Strong	Biomarker	[32]
CDH4	OT8LH3HN	Strong	Biomarker	[33]
HIC1	OTI9TWY4	Strong	Biomarker	[30]
HMGB3	OTCJ2EZY	Strong	Altered Expression	[10]
KLK10	OTD573EL	Strong	Altered Expression	[34]
NID2	OTHC33FF	Strong	Posttranslational Modification	[35]
RNF2	OTFPLOIN	Strong	Altered Expression	[36]
SHMT2	OT5NCAZN	Strong	Altered Expression	[37]
BLM	OTEJOAJX	Definitive	Genetic Variation	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 31 DOT(s)

References

1	Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.Cancer Res. 2003 Mar 1;63(5):994-9.
2	Somatic mutation of the Caspase-5 gene in human lung cancer.Int J Mol Med. 2003 Oct;12(4):443-6. doi: 10.3892/ijmm.12.4.443.
3	Biomarkers for personalized oncology: recent advances and future challenges.Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30.
4	Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer.Cancer Lett. 2001 Mar 10;164(1):97-104. doi: 10.1016/s0304-3835(00)00716-3.
5	Human gastrin-releasing peptide receptor gene regulation requires transcription factor binding at two distinct CRE sites.Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G153-G162. doi: 10.1152/ajpgi.00036.2008. Epub 2008 May 15.
6	Assessment of clonality in gastrointestinal cancer by DNA fingerprinting.J Clin Invest. 1988 Nov;82(5):1532-7. doi: 10.1172/JCI113762.
7	A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.Am J Cancer Res. 2018 Apr 1;8(4):610-623. eCollection 2018.
8	Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.PLoS One. 2017 Dec 19;12(12):e0189953. doi: 10.1371/journal.pone.0189953. eCollection 2017.
9	Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation.Chem Biol Interact. 2014 Mar 25;211:36-43. doi: 10.1016/j.cbi.2014.01.004. Epub 2014 Jan 16.
10	Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer.J Cell Physiol. 2020 Apr;235(4):3438-3446. doi: 10.1002/jcp.29233. Epub 2019 Oct 16.
11	N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding.Int J Cancer. 2004 Dec 10;112(5):815-22. doi: 10.1002/ijc.20483.
12	EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma.Hum Pathol. 2005 Jan;36(1):74-81. doi: 10.1016/j.humpath.2004.10.015.
13	Comparative integromics on non-canonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells.Int J Mol Med. 2007 Sep;20(3):405-9.
14	Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors.Cancer Res. 1997 Jun 15;57(12):2350-3.
15	Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer.Oncogene. 2005 Dec 1;24(54):8012-24. doi: 10.1038/sj.onc.1208946.
16	Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents.Mutat Res Genet Toxicol Environ Mutagen. 2017 Nov;823:45-57. doi: 10.1016/j.mrgentox.2017.08.004. Epub 2017 Sep 12.
17	GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest.Oncogene. 2011 Apr 7;30(14):1716-26. doi: 10.1038/onc.2010.550. Epub 2010 Dec 6.
18	Cloning and characterization of a p53 and DNA damage down-regulated gene PIQ that codes for a novel calmodulin-binding IQ motif protein and is up-regulated in gastrointestinal cancers.Cancer Res. 2005 Dec 1;65(23):10725-33. doi: 10.1158/0008-5472.CAN-05-1132.
19	An abnormally high expression of ISL-1 represents a potential prognostic factor in gastric cancer.Hum Pathol. 2015 Sep;46(9):1282-9. doi: 10.1016/j.humpath.2015.05.006. Epub 2015 May 27.
20	LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers.Int J Oncol. 2008 Sep;33(3):461-8.
21	Expression of unusual immunohistochemical markers in mucinous breast carcinoma.Acta Histochem. 2017 Apr;119(3):327-336. doi: 10.1016/j.acthis.2017.03.002. Epub 2017 Mar 21.
22	Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer.Cancer Detect Prev. 2008;32(3):236-50. doi: 10.1016/j.cdp.2008.08.002. Epub 2008 Sep 17.
23	PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer.Clin Cancer Res. 2007 Aug 15;13(16):4786-94. doi: 10.1158/1078-0432.CCR-07-0305.
24	Control of octreotide release from silk fibroin microspheres.Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:820-828. doi: 10.1016/j.msec.2019.05.004. Epub 2019 May 3.
25	Cohesin Rad21 mediates loss of heterozygosity and is upregulated via Wnt promoting transcriptional dysregulation in gastrointestinal tumors.Cell Rep. 2014 Dec 11;9(5):1781-1797. doi: 10.1016/j.celrep.2014.10.059. Epub 2014 Nov 20.
26	Analysis of fecal DNA methylation to detect gastrointestinal neoplasia.J Natl Cancer Inst. 2009 Sep 16;101(18):1244-58. doi: 10.1093/jnci/djp265. Epub 2009 Aug 21.
27	Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.J Immunother Cancer. 2019 Jan 10;7(1):8. doi: 10.1186/s40425-018-0476-x.
28	Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression.PLoS Genet. 2008 Jun 13;4(6):e1000092. doi: 10.1371/journal.pgen.1000092.
29	Expression analysis of proline rich 15 (Prr15) in mouse and human gastrointestinal tumors.Mol Carcinog. 2011 Jan;50(1):8-15. doi: 10.1002/mc.20692.
30	Loss of a single Hic1 allele accelerates polyp formation in Apc(716) mice.Oncogene. 2011 Jun 9;30(23):2659-69. doi: 10.1038/onc.2010.633. Epub 2011 Feb 7.
31	An alternatively spliced form of apobec-1 messenger RNA is overexpressed in human colon cancer.Gastroenterology. 1998 Nov;115(5):1096-103. doi: 10.1016/s0016-5085(98)70080-0.
32	CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.Arch Pathol Lab Med. 2017 Jan;141(1):144-150. doi: 10.5858/arpa.2015-0404-OA.
33	Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.Cancer Res. 2004 Nov 15;64(22):8156-9. doi: 10.1158/0008-5472.CAN-04-3000.
34	Upregulated KLK10 inhibits esophageal cancer proliferation and enhances cisplatin sensitivity invitro.Oncol Rep. 2015 Nov;34(5):2325-32. doi: 10.3892/or.2015.4211. Epub 2015 Aug 20.
35	Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer.Mol Cancer. 2007 Feb 28;6:17. doi: 10.1186/1476-4598-6-17.
36	Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.Mod Pathol. 2006 May;19(5):684-94. doi: 10.1038/modpathol.3800577.
37	High expression of SHMT2 is correlated with tumor progression and predicts poor prognosis in gastrointestinal tumors.Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9379-9392. doi: 10.26355/eurrev_201911_19431.
38	The coding region of the Bloom syndrome BLM gene and of the CBL proto-oncogene is mutated in genetically unstable sporadic gastrointestinal tumors.Cancer Res. 1998 Sep 1;58(17):3777-81.